Study on treatment method, age group, complications, and outcome of meningiomas and hemangioblastomas using DPC
Not Applicable
- Conditions
- Meningioma, Hemangioblastoma
- Registration Number
- JPRN-UMIN000038486
- Lead Sponsor
- Graduate School of Biomedical and Health Sciences, Hiroshima University Department of Neurosurgery
- Brief Summary
End of follow-up
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 10000
Inclusion Criteria
Not provided
Exclusion Criteria
Non-surgical cases
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Barthel Index(BI)
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways does DPC target in meningiomas and hemangioblastomas with NF2/VHL mutations?
How does DPC-based treatment compare to standard-of-care therapies for meningioma and hemangioblastoma outcomes?
Which biomarkers correlate with favorable prognosis in DPC-treated meningioma/hemangioblastoma patients?
What adverse events are associated with DPC therapy in meningioma and hemangioblastoma clinical cohorts?
Are there combination strategies involving DPC and anti-VEGF agents for VHL-related hemangioblastomas?